Ligustrazine Nanoparticle Hitchhiking on Neutrophils for Enhanced Therapy of Cerebral Ischemia-Reperfusion Injury

作者：Mu, Qingchun^*; Yao, Kai; Syeda, Madiha Zahra; Zhang, Min; Cheng, Qian; Zhang, Yufei; Sun, Rui; Lu, Yuting; Zhang, Huamiao; Luo, Zhicheng; Huang, Hanning; Liu, Xiaojing; Luo, Chunmei; Zhu, Xiulong; Wu, Shuyu; Cui, Liao; Huang, Chunming^*; Chen, Xiaoyuan^*; Tang, Longguang^*

来源：Advanced Science, 2023, 10(19).

DOI：10.1002/advs.202301348

• cerebral ischemia-reperfusion injury
• drug delivery
• ligustrazine
• neutrophils
• reactive oxygen species (ROS)

Ischemic stroke is a refractory disease that endangers human health and safety owing to cerebral ischemia. Brain ischemia induces a series of inflammatory reactions. Neutrophils migrate from the circulatory system to the site of cerebral ischemia and accumulate in large numbers at the site of inflammation across the blood-brain barrier. Therefore, hitchhiking on neutrophils to deliver drugs to ischemic brain sites could be an optimal strategy. Since the surface of neutrophils has a formyl peptide receptor (FPR), this work modifies a nanoplatform surface by the peptide cinnamyl-F-(D)L-F-(D)L-F (CFLFLF), which can specifically bind to the FPR receptor. After intravenous injection, the fabricated nanoparticles effectively adhered to the surface of neutrophils in peripheral blood mediated by FPR, thereby hitchhiking with neutrophils to achieve higher accumulation at the inflammatory site of cerebral ischemia. In addition, the nanoparticle shell is composed of a polymer with reactive oxygen species (ROS)-responsive bond breaking and is encased in ligustrazine, a natural product with neuroprotective properties. In conclusion, the strategy of hitching the delivered drugs to neutrophils in this study could improve drug enrichment in the brain, thereby providing a general delivery platform for ischemic stroke or other inflammation-related diseases.

• 单位
  1; 哈尔滨医科大学; 南方医科大学; 河北医科大学; 广东医学院; 浙江大学; 海南医学院